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SUMMARY 
Serum thymidine kinase 1 (TK1) activity is used as a tumor marker in disease monitoring in 
veterinary and human medicine. TK1, an intracellular enzyme, is involved in a salvage 
pathway of DNA precursor synthesis.  
TK1 is used in DNA precursor production by catalyzing the transfer of the gamma-phosphate-
group from a phosphate-donor to the 5´ - hydroxyl-group of thymidine forming thymidine-
monophosphate. Nucleoside monophosphosphates are finally converted into thymidine-
triphosphates. TK1 activity significantly rises in the G1 and the S phase of the cell cycle. 
Thus, TK1 is found in dividing cells, and in the blood as an extracellular form of the enzyme.  
Two different TK isoforms have been identified in animal cells, one in the cytosol (TK1) and 
the other in mitochondria (TK2). TK1 plays a key role in cell-division, as a step in the 
reaction chain to introduce thymidine in to DNA. Thymidine is degraded into smaller 
molecules and secreted. It is found in body fluids, as a result. 
Due to the noticeable proliferative activity in tumor cells, TK1 enzyme activity is increased in 
this type of cells. Increased TK1 activity is a reflection of a high proportion of cells in S-
phase of the cell-cycle. Since increased TK1 activity can be measured in serum, TK1 is a 
useful marker in diagnostics of neoplastic diseases. TK1 activity provides valuable 
information regarding disease prognosis and treatment results.  
Increase in TK1 levels are considered to be a sensitive and valuable marker for not only cell 
proliferation but also malignancy monitoring in clinical medicine. 
In addition, there are viruses able to induce TK production and elevated serum TK levels can 
be found in a variety of neoplasias as reported in clinical studies. Most of these studies 
concerned hematologic malignancies. E.g. TK1 is a valuable marker in non-Hodgkin's 
lymphoma. TK reflects clinical staging and provides noteworthy prognostic information. 
In both veterinary and human medicine a radioactive based test (Thymidine kinase radio-
enzymatic assay: TK-REA) is commercially available to assess TK1 serum activity. For 
example, it is used to determine TK1 serum activity in dogs. However, TK-REA requires 
handling of radioactive material and costs 500 kr (€ 58) per test, which limits its use in 
veterinary clinical diagnostics and disease monitoring.  Antibodies have been used to measure 
the TK1 serum concentration. Analysis of this type has been successful in canine- and human- 
medicine and would be valuable to evaluate in feline-medicine. 
Since TK1 serum has proven useful in canine- and human- medicine the hypothesis was that 
feline would be able to serve as a valuable biomarker in feline clinical medicine. 
The aim of the study was to evaluate whether feline TK1 has the potential to become a 
valuable biomarker in feline clinical practice.  In order to evaluate TK1 as a biomarker, the 
enzyme’s activity in serum was measured with [3H]-dThd phosphorylation assay and with the 
commercially available TK-REA assay. The results were compared. The study is a first step 
towards better understanding the feline TK1’s role in disease diagnostics, disease monitoring, 
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and as a proliferation biomarker in neoplastic diseases. Significant correlation was observed 
between the [3H]-dThd phosphorylation assay results and the commercially available TK-
REA assay results. A correlation of 0.97 was found between the assay and the commercially 
available TK-REA measured activity. The [3H]-dThd phosphorylation assay showed a mean 
value of 2.04 pmol/min/mL in sera from cats with diseases, with a standard deviation of 2.07. 
The level of TK1 activity for healthy cats was not detectable, using a cut of value at 0.8 
pmol/min/mL 
Both assays show a significant increase in TK activity in cats with lymphoma, leukemia and 
cystitis versus clinically healthy cats, signifying that TK may serve as a future diagnostic tool 
in clinical practice. However, the discrepancy in activity level between a cat with lymphoma 
and a healthy cat was not as significant as that between a dog with lymphoma and a healthy 
dog.  
In conclusion, a high TK serum activity level is greatly indicative of a hematopoietic 
neoplasia diagnosis, while there is a low predictability for cats with low TK serum activity 
level. The findings show that feline TK1 has the potential to become a valuable biomarker in 
clinical practice. These finding in combination with the overview of the lymphoma diagnostic 
challenges indicate that TK1 has the potential to become a valuable biomarker in clinical 
practice.  
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SAMMANFATTNING 
Mätning av aktivitet av serum thymidinkinas 1 (TK-1) används som biomarkör inom human- 
och veterinär- medicinen. Det intracellulära enzymet TK-1 ingår i cellens DNA-syntes ”The 
Salvage Pathway” och uttrycks under cellcykeln. TK-1 aktiviteten är som högst i cellen då 
DNA syntesen är aktivast mellan G1- och S-fasen av cellcykeln. I normala celler avtar 
enzymets aktivitet när cellen påbörjar G2-fasen av cellcykeln. Vid neoplastiska och 
inflammatoriska sjukdomar är TK-aktivitet i cellen högre då cell-proliferationen och DNA-
syntesen är intensiv. Den förhöjda TK1 aktiviteten i serum går att mäta vilket gör TK-1 till en 
brukbar biomarkör för diagnostik av inflammatoriska och neoplastiska sjukdomar. TK1 som 
biomarkör kan användas som hjälpmedel för att ställa diagnos, bedömning av prognos och för 
att utvärdera insatt behandling.  
I både veterinär- och human-medicin finns ett radioaktivt test tillgängligt för att mäta TK1 
aktivitet i serum: TK-REA. TK-REA används tex för att mäta TK1 aktivitet i hundar med 
misstänkt neoplastiska sjukdomar. Dock kräver TK-REA radioaktiva ämnen och kostar 500 kr 
per prov, vilket begränsar dess användning i veterinär kliniska sammanhang. Antikroppar har 
används för att mäta serum nivåer av TK1. Denna typ av analys har varit framgångsrik som 
biomarkör inom human- och hund- medicin och skulle med stor sannolikhet vara användbar 
även inom katt-medicin. 
Eftersom TK1 aktivitet i serum har visat sig vara en användbar biomarkör i både human- och 
hund-medicin var hypotesen att TK1 aktivitet i serum skulle visa sig ha potentialen att kunna 
bli en brukbar biomarkör inom katt-medicin.  
Målet med denna studie var att utvärdera katt TK1 som en användbar biomarkör i klinisk 
diagnostik. För att kunna utvärdera katt TK1 som biomarkör mättes kattserum aktivitet med 
[3H]-dThd fosforylering testet och TK-REA testet för att sedan kunna jämföra resultaten. 
Studien, är ett första steg mot att utvärdera katt TK1 som biomarkör för att diagnostisera 
neoplastiska och inflammatoriska sjukdomar, följa upp insatt behandling och bedöma 
prognosen.   
Resultaten mellan [3H]-dThd fosforylering testet och TK-REA testet hade en korrelation på 
0.97. [3H]-dThd fosforylering testet hade en genomsnittlig aktivitet på 2,04 pmol/min/mL 
med en genomsnittlig standardavvikelse på 2.07 hos prover från sjuka katter. De friska 
katternas TK1 serum aktivitet låg under detektionsgränsen på 0.8 pmol/min/mL.  
Båda testerna visar förhöjd TK1 serum aktivitet hos katter med lymfom, leukemi och cystit 
jämfört med friska katter, vilket indikerar att TK1 har potential att kunna bli en användbar 
biomarkör inom kattmedicin. Dock så är skillnaden i aktivitet mellan en katt med lymfom och 
en frisk katt inte lika markant som hos hund.  
Konklusion, en hög TK1 serum aktivitet är indikativ för en neoplastisk diagnos, medan 
diagnosen är osäker vid låg aktivitet. Resultatet från testerna i kombination med 
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sammanställningen av de diagnostiska utmaningarna visar att TK1 har potential att bli en 
brukbar biomarkör i klinisk medicin. 
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INTRODUCTION 
DNA Replication and the role of thymidine kinase 
Thymidine kinase (TK) is one among several enzymes involved in the synthesis of DNA 
precursors. TK catalyzes the phosphorylation of thymidine (deoxythymidine/ dTdR) to 
thymidine 5’-phosphate (dTMP) (Uzman et al., 2012). dTMP is incorporated into DNA after 
further phosphorylation. TK activity can be measured by using radioactive labelled 
thymidine.        
Deoxyribonucleic acid (DNA) precursor synthesis in cells follows de novo-pathway or 
salvage pathway. In the de novo-pathway, pyrimidine and purine ribonucleotides are reduced 
to deoxyribonucleotides by the enzyme ribonucleotide reductase. If the de novo-pathway is 
obstructed, the cells utilize the salvage pathway in order to stay alive. For deoxy- pyrimidine 
synthesis, the salvage pathway forms thymidine monophosphate from thymidine using 
thymidine kinase. The cells die if both pathways are being obstructed. 
Purine (bases A and G) and pyrimidine (bases C and T) deoxyribonucleotides, making up the 
two groups of nitrogenous bases (Calladine et al., 2004). Purine and pyrimidine, two aromatic 
organic compounds, are synthesized by de novo pathway. Salvage pathways recover 
nucleosides and bases that are made during the degradation of nucleic acids. Some tissues 
cannot undergo de novo synthesis why the salvage pathway plays an essential role. The 
salvaged nucleosides and bases can be converted back into nucleotides. The salvage pathway 
uses substrates for free purines from the hydrolysis of nucleotides, or thymidylate (dTMP) 
produced by thymidine kinase from thymidine, instead of the typical path where 
deoxyuridylate (dUMP) is methylated using thymidylatesynthetase into thymidylate (dTMP). 
Biomarkers 
Definition of a biomarker: “A biomarker is a characteristic that can be objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention” (Puntmann , 2009). 
In oncology trials, serum analysis constitutes the most used source of biomarkers  (Goulart et 
al., 2007). Safety, patient acceptance, easy accessibility, and the fact that it is relatively 
inexpensive, are contributing determining factors of a practical biomarker. Actual tissue of a 
tumor is the second leading biomarker. Biopsies from normal tissue can also represent useful 
biomarker sources as they include sites more accessible than actual tumors while providing 
cells and tissues with modulatory effects of a drug.  
In veterinary medicine, diagnosis of diseases and appropriate therapeutic treatment are 
clinical challenges. In order to assist in diagnostics, an ideal biomarker for the corresponding 
disease should have appropriate sensitivity and specificity to differentiate between healthy 
and sick patients. Thus, provide reliable information about the disease progression, how it 
responds to therapy, and predict the recurrence of the disease. 
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Serum TK1 as a biomarker 
Extreme and unrestrained cell-proliferation is a hallmark of cancer. Several types of cell-
proliferation markers have been used in diagnosis, prognosis, monitoring of therapy outcome 
and follow-up in clinical oncology. Few tumor markers are useful in all cases, with the S 
phase-specific TK1 being an exception. TK1 expression is closely correlated to the overall 
level of proliferation. Several commercial serum TK1 activity assays have proven valuable in 
clinical practice (Von Euler & Eriksson, 2011). 
Blood biomarkers include infectious disease biomarkers used when inflammatory mediators 
are released into the blood at the infection site, and cell proliferation biomarkers such as 
tumor markers (Sharif, 2012). Tumor markers are any substance found in the body when 
malignant cells are present.  
The activity of TK1 in late the G1- and the early S -phase of dividing cells clarifies the 
elevated enzyme levels in various tumors, as they typically contain fewer quiescent cells 
(cells in a resting phase G0) than do regular tissue (Hallek et al., 1992). Hence, serum 
elevations of TK1 levels have been detected in several malignancies. 
A tumor is an abnormal mass of body tissue that lacks body function. Tumors are typically 
classified as benign or malignant. A benign tumor is not classified as cancer. It grows slowly, 
does not spread, nor does it invade surrounding tissue. Once a benign tumor is entirely 
removed, it typically does not recur. A malignant tumor, on the contrary, is cancer that has the 
capability to spread through metastases. Some "benign" tumors may later transform into 
malignant tumors, due to further genetic changes in subpopulations of neoplastic cells of the 
tumor. Hence, early cancer diagnosis allows for early treatment and greater survival rate.. 
Appropriate tumor markers can considerably reduce the diagnostic lead time, and serve as a 
screening tool for the prevalence of malignancy in populations at risk and apparently healthy 
populations. Good markers will allow for early detection of tumors and thus a better chance 
for appropriate therapy. These markers may also be used to evaluate the therapy and predict 
any possible disease recurrence. 
In a number of studies, serum TK changes have been found to parallel and/ or anticipate the 
clinical course, i.e. the response to treatment and possible relapse, of low-grade non-
Hodgkin's lymphoma in longitudinal individual patient observations (Hallek et al., 1992) 
A health screening study including more than 35,000 people confirms that serum TK1 
concentration can be a valuable biomarker for detecting future potential malignancies (Chen 
et al., 2011). Serum TK1 assay can distinguish between sick people with tumor, people with 
non-malignant proliferation diseases, and healthy individuals. 
TK-REA is an established tool for tumor diagnosis and prognosis in human medicine that has 
been used for several decades (Von Euler & Eriksson, 2011). More recently, it has also been 
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used in dogs with malignant lymphoma. Serum TK1 activity differs noticeably between 
healthy dogs and dogs with lymphoma.  
High levels of TK1 can be detected in the sera of animals and humans with tumors; thus, TK1 
activity in serum is used as a prognostic marker for several types of tumors, foremost 
leukemia and lymphoma (Sharif & von Euler et al., 2012). 
Serum TK1 protein level assessments in tumors provide accurate information about the cancer 
patient’s prognosis (He et al., 2010). TK1 protein level assessment can also be used for 
monitoring tumor therapy and as an early detector of diseases such as cancer. Serum TK1 
protein values correlate to remission after chemotherapy and surgery. The TK1 intracellular 
expression in human breast tumors is used to predict the survival rate of patients with breast 
cancer. 
The cytoplasmatic enzyme TK1 is a candidate for the early detection of tumor cell division 
and proliferation (Aufderklamm et al., 2011). The use of TK1 antibodies has been 
investigated in different studies including different types of solid tumors. This makes TK1 
feasible for monitoring of therapeutic outcome and efficacy especially in the post-surgery 
phase of treatment. 
As TK1 is expressed in proliferating cells during the DNA synthesis, it can be detected in 
both malignant and non-malignant cells (Chen et al., 2011). TK1 serum concentration and its 
activity are elevated in the case of cancer patients, while TK1 serum concentration and its 
activity in healthy people are low or undetectable. Though, in the case of human patients with 
acute sickness such as inflammation or infection, or experiencing other physiological changes 
(menstruation, surgery, or blood-donation), TK1 can increase in the momentarily. The reasons 
for differences in STK1 levels of sick people and healthy people are still not entirely known. 
A likely explanation is related to cell death. Regular healthy cells die during the G1/G0 stage 
of the cell cycle, when the intra-cellular levels of TK1 are low. Tumor cells can die in the 
S/G2 stage of the cell cycle, when TK1 levels are high, causing more serum TK1. Another 
explanation is a factor in serum, which acts differently in healthy people compared to sick 
people, affecting the stability of serum TK1. Since serum TK1 increases when people have 
infections or inflammations as a result of the activation of the immune system, it may be 
possible that a part of the increased serum TK1 levels of cancer patients results from the 
stimulated immune system and not only from the cancer cells. Hence, when interpreting the 
implications of an increase of STK1 as a malignancies development risk, reasons for the short 
term increase in STK1 levels other than possible malignancies should be taken into account. 
Thus, the medical history of the patient is essential. 
Aim of the study 
Distinguishing between the diagnosis lymphoma, IBD and allergies can be a challenge. It is 
important to arrive at the accurate diagnosis since the therapy varies for different pathological 
conditions. Thus, the outcome of the clinical treatment is dependent on an accurate diagnosis 
and the biomarkers involved.  TK1 activity in serum has proven to be a valuable diagnostic 
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tool in human and canine medicine, which may also be the case for feline medicine.  The aim 
of the study was to evaluate whether feline TK1 serum activity has the potential to become a 
valuable biomarker in feline clinical practice and to summarize the clinical diagnostic 
challenges of lymphoma versus IBD.  
A significant correlation was found between TK-REA and [
3
H]-dThd assay when measuring 
serum TK1 activity in dogs with hematological tumors (Sharif & von Euler et al., 2012). 
The study is a first step towards defining the role of TK1 in feline disease diagnostics, disease 
monitoring, and as a proliferation biomarker in neoplastic diseases. TK1 activity in serum was 
measured with the [
3
H]-dThd phosphorylation assay and compared with the commercially 
available feline TK-REA assay results.  Temperature, pH, and time were altered in an attempt 
to optimize the [
3
H]-dThd phosphorylation assay.  
BACKGROUND 
Feline Cancer 
Cancer is a one of the major causes of mortality and sickness in domestic animals (Argyle et 
al., 2008). Current reports indicate prevalence increase of cancer in cases of dogs and cats, 
partly due to the increased life span of domestic animals. Life span has increased due to 
infectious disease control, vaccination, and improved nutrition. Thus, there is an increased 
expectation of the veterinary practitioner, to be able to diagnose and treat patients with cancer 
in general practice. 
Compared to dogs and other domestic animals, cats have higher cancer rates (Eldredge et al., 
2008). Feline cancers typically occur in middle-aged to older cats at the age of 10 to 15 years. 
However, lymphoma being an exception occurs most often in young cats. Besides skin and 
breast tumors, most feline cancers are not visible by outward inspection. Skin and breast 
neoplasms can be detected by inspection and palpation. Feline leukemia virus and the feline 
immunodeficiency virus are assumed to be a contributing factor to the high cancer rate in cats. 
Common involvement sites are lymph nodes (i.e. lymphoma) and circulating blood cells (i.e. 
leukemia). Any organ or body tissue of the cat can be affected. The leukemia virus of cats 
(FeLV) most likely accounts for fifty percent of all internal cancers, lymphoma being the 
majority (Eldredge et al., 2008). Low immunity level associated with feline leukemia virus 
infection certainly contributes to the high prevalence of secondary diseases. The feline 
leukemia virus is associated with other serious cat diseases such as toxoplasmosis, spinal cord 
cancers, glomerulonephritis, feline infectious peritonitis, and anemia. 
FELINE CANCER FACTS 
 Hemopoietic tumors are the most commonly diagnosed feline neoplasm type, 
accounting for about 35% of all diagnosed tumors and is directly related to Feline 
Leukemia Virus (Argyle et al., 2008). 
 32% of cats over 10 years old will die from cancer. 
 9 
 
 Approximately 0,025% of female cats will develop mammary cancer 
 17 % of feline cancers are mammary related. 
 Feline lymphoma will affect 0,002% of all cats.  
 FeLV positive cats have a 60% higher risk than healthy cats to be affected by 
lymphoma. 
 10% of feline tumors are located in the mouth. 
 Vaccination related sarcomas has a prevalence between in 0,1% to 0,01% in cats  
 25 % of all cancers in cat are cancers of the skin, with approximately 50-65 % being 
malignant (Eldredge et al., 2008). 
Skin tumors are common in cats (Eldredge et al., 2008). Many feline tumors of the skin are 
benign; however, the prevalence of skin cancer accounts for 25% of feline cancers. Next in 
incidence is breast (17 %). Cancer is a condition, characterized by, cell division and tissue 
growth that transpires at the expense of organ-specific functions. As an example, under the 
microscope a feline kidney-cancer is biopsied and found to be composed of tissue that only 
slightly resemblance that of normal cells of the kidney. The tumor kidney mass does not 
function as kidney tissue, and does not produce any urine. If the cancer is left untreated, it will 
eventually replace the kidney tissue while spreading to other parts of the body. In time, it will 
render the cat in a state of death. Cancer is staged according to the malignancy degree. Low-
grade tumor grows locally and can grow to a large size. Low-grade tumors extend to remote 
organs late in the course of the sickness. High-grade tumors spread early in the course of the 
sickness, while the primary tumor is hardly detectable. 
One of the most common forms of malignancies encountered in small animal practice is 
lymphoma (Argyle et al., 2008). Lymphoma is characterized by lymphoid cell malignant 
proliferation, which may occur in organs with lymphoid tissue. Lymphoma (also known as 
malignant lymphoma or lymphosarcoma) is also one of the more common neoplasms of the 
dog. 
Feline Lymphoma 
Feline lymphoma is a systemic, i.e. can involve multiple anatomic sites, neoplastic disease of 
the lymphoid system (Argyle et al., 2008). Etiology is in many cases unknown.  Retroviral 
infection such as FeLV and FIV increase risk of lymphoma. In order to get a reliable 
prognosis, staging based on the anatomic site is indicated. Organ that can be involved are: 
extra nodal, gastrointestinal, CNS, nasal, mediastinal, multi-centric or renal. Chemotherapy 
systemically may be indicated when treating lymphoma that has spread to multiple organs or 
in case of diffuse disease. Low-grade gastrointestinal lymphoma (i.e. small-cell also called 
lymphocytic) is an indolent type of neoplasm with a good prognosis with proper therapy 
compared to high-grade gastrointestinal lymphoma (i.e. large-cell also called lymphoblastic). 
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Biopsy may be used to differ between these two types of neoplasm. It is important to establish 
which type it is, as the treatment plan differs between the two types of neoplasm. Lymphoma 
recurrence versus mitigating therapy is more complicated in feline patients than it is in dogs. 
The risk of getting feline lymphoma has been reported to increase till 1.5 years of age, 
followed by a stable flat risk rate for the rest of the cat’s lifespan (Carolyn J. Henry et al., 
2010). Lymphoma appears in cats of various breed, age, or sex. Siamese have been reported 
to be over-represented as a breed. Burmese (risk rate of 3.1) and Manx (risk rate of 4.6) 
appear to be at higher risk.  Intact females (risk rate of 0.7) appear to be at a lower than-
expected risk rate. Viral causes of lymphoma in cats are well defined. Simultaneous feline 
leukemia virus infection and feline immunodeficiency virus infection increase the risk factor 
77 fold. Feline leukemia virus infection increases the risk factor 62 fold. Feline 
immunodeficiency virus infection increases the risk factor six fold. Depending on the duration 
of exposure, cigarette smoke also increases the risk of getting lymphoma. Chronic 
gastrointestinal inflammation has also been proposed to be a cause of gastrointestinal 
lymphoma. Immunosuppressive treatment in association with renal transplantation has also 
been associated with lymphoma development. Treatment for vaccine-associated sarcoma has 
also been reported to be associated with the development of lymphoma. 
FeLV-related mediastinal lymphoma tends to be more prevalent in younger cats while older 
cats tend to have non-FeLV-related intestinal lymphoma (Carolyn J. Henry et al., 2010).  
Lymphoma cats can often be categorized in two groups; young cats with feline leukemia virus 
(FeLV)-associated disease (Carolyn J. Henry et al., 2010). The young lymphoma cats often 
have respiratory signs due to pleural effusion and enlargement of the mediastinal lymph node. 
Older cats often have extra nodal lymphoma or gastrointestinal lymphoma non-FeLV related. 
Lymphoma in an extra nodal location can have a variety of clinical signs such as masses that 
destroy bone or solitary masses in typical locations: e.g., cutaneous. Hypoadrenocorticism and 
hypercalcemia may be clinical signs of feline lymphoma, but not as common as for dogs. 
Depending on geographic location the feline lymphoma characteristics and clinical symptoms 
may vary considerably. 
Feline Lymphoma and FeLV 
Based on viral interference with super infection, FeLV isolates are categorized into 3 groups 
(Argyle et al., 2008). The groups probably define envelope types using diverse cellular 
receptor molecules for viral entry in to the host cell. FeLV A can only infect feline cells 
(ecotropic) and exemplifies the dominant form of the virus. FeLV B can also infect human 
cells (polytropic) and is common in feline virally induced lymphoma cases. FeLV B are 
believed to arise from recombination measures between feline endogenous sequences in the 
genome and FeLV A. FeLV C is believed to arise by mutation of the envelope gene in FeLV 
A. It is not transmitted in nature and is distinctively linked to feline pure red cell aplasia 
(PRCA). The main source of infection is persistent viremic individuals. FeLV is transmitted 
by close social contact and is continuously secreted in the saliva. FeLV is also transmitted 
vertically from a carrying queen to her kittens (congenitally). During the first weeks after the 
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viral exposure, the outcome of infection is determined contingent on interaction between the 
cat’s immune system and the FeLV. The potential outcomes consist of latent infection, 
persistent viral infection, and viral clearance with FeLV-immunity. Persistently viremic 
individuals may develop virus related diseases such as lymphomas, being the most common 
tumor of cats, and leukemia.  Mechanism of tumorogenesis comprises of insertions of viral-
DNA on cellular oncogenes e.g. myc and suppression of the cat’s immune-system. 
Approximately 80 percent thymic lymphoma cats are viremic, 60 percent of alimentary 
lymphoma cats are viremic, and 30 percent of alimentary lymphoma cats are viremic. The 
viruses may be part of an initiating event before being vacated by the host’s immune-system. 
FeLV is also associated with immunosuppression, bone marrow failure, and reproductive 
failure. The pathogenesis of these diseases is yet to be understood. 
Lymphoma and FIV 
FIV is a lentivirus (Argyle et al., 2008). Lentivirus is a retrovirus that typically causes 
diseases with a long incubation period. Examples of lentiviruses are HIV, Maedi-Visna, FIV, 
and equine infectious anemia. FIV has been linked with feline neoplasm, particularly 
lymphomas. This can generally be explained by the immunosuppression of the host’s 
immune-system caused by FIV. 
Diagnostics and Staging of Feline Lymphoma 
In order to arrive at the correct diagnosis low-grade alimentary lymphoma (LGAL) requires 
histological biopsies assessment, whereas intermediate- (IGAL) and high-grade (HGAL) 
alimentary lymphoma (AL) can be diagnosed by cytology of aspirates from mesenteric or 
intestinal lymph node (Russell et al., 2012). 
With different locations such as mediastinal, gastrointestinal, multicentric, nasal, and extra 
nodal, each type of lymphoma seems to have clinically diverse development and possibly 
suitable therapy (Carolyn J. Henry et al., 2010). Each type of lymphoma presents exceptional 
therapeutic challenges. Diagnosis of mediastinal lymphoma is made of mediastinal mass 
aspirate cytology or pleural fluid cytology. Biopsy of the medistinal lymph node is 
complicated by location within the confines of the thoracic cavity. There is a risk of 
puncturing a vascular structure or a lung. Extra nodal and multi-centric lymphoma can 
generally be diagnosed by biopsy or fine-needle aspirate. Immunohistochemistry on 
histopathology of biopsy specimens of a surgically or endoscopically collected sample is used 
to diagnose gastrointestinal lymphoma. Nasal lymphoma typically requires biopsy to confirm 
the diagnosis. Nasal lymphoma may have a characteristic appearance on skull CT. In the case 
when histopathology is inconclusive, T-cell receptor gene or immunoglobulin gene 
rearrangement clonality valuation can aid in diagnostics. Once the diagnosis is established, a 
thorough staging is appropriate in order to apply appropriate treatment and reduce toxicity. 
Biological Behavior/Metastasis 
Feline lymphoma, just like in dogs, tends to spread systemically (Carolyn J. Henry et al., 
2010). Typically, it is the non-Hodgkin’s form of lymphoma. However, Hodgkin’s lymphoma 
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with Reed-Sternberg cells has also been reported. Due to the uncommon anatomic symptoms 
of lymphoma in cats, the WHO standard staging scheme is less prognostic than in the case of 
canine lymphoma. Immunophenotype may differ by etiology and by location. Among the 
retrovirus-induced neoplasms, FeLV-associated lymphomas tend to be of T-cell origin, where 
FIV-associated lymphomas tend to be of B-cell lineage. FIV-related lymphomas tend to 
involve extra nodal locations whereas FeLV-associated tumors typically involve the 
mediastinum. 
Nasal lymphomas tend to be of B-cell origin, and curable by radiation therapy. Nasal 
lymphomas may spread systemically (Carolyn J. Henry et al., 2010). Immunophenotype 
(contrary to dogs), age, gender, weight, FIV status, and tumor-stage are not useful prognostic 
factors. 
Feline Gastrointestinal Lymphoma 
Feline gastrointestinal lymphoma is characterized by intestinal and/ or gastric infiltration with 
or without the mesenteric lymph node being involved (Argyle et al., 2008). Gastrointestinal 
lymphoma is one of the common types of feline lymphoma. Gastrointestinal lymphoma can 
present itself as a diffuse infiltration of extensive areas of the bowel or as a solitary mass 
lesion. Clinical signs may be nonspecific, including diarrhea, vomiting, weight loss, and 
anorexia. Patients that have formerly been diagnosed with lymphoplasmacytic gastroenteritis 
may end up developing gastrointestinal lymphoma. Most of the alimentary lymphoma cats are 
FeLV negative. Removing apparent solitary lesions by surgical excision is not to be 
recommended since the neoplasm frequently spreads beyond the detectable lesion. In many 
cases, the lymphoma is diffuse. In the case of chemo-resistant obstructive lesions or 
perforated lesions, surgical excision must be considered. 
In some cases it is difficult to distinguish inflammatory bowel disease from low-grade small-
cell lymphoma purely on pathological assessment of the affected gut (Argyle et al., 2008). 
However, a number of groups have described a PCR (polymerase chain reaction) based test 
that determines the clonality of biopsied tissues by analyzing, for example, the T cell receptor 
gamma variable gene. Tumor lesions are clonal in origin and therefore have a different PCR 
pattern to polyclonal inflammatory lesions. 
Therapy and Prognosis 
For renal-, multi centric-, thymic- and high-grade gastrointestinal- forms of lymphoma, the 
therapy options are similar to those of canine patients (Argyle et al., 2008). 
Cyclophosphamide, vincristine, and prednisone (COP regime) provide prolonged remission 
and prolonged survival times. As for canine patients, protocols that include doxorubicin may 
give better clinical results. However, this is not widely supported by clinical experience.  
Doxorubicin can be nephrotoxic to feline patients, why many oncologists use COP-based 
protocol for treating feline patients with lymphoma. In the case of renal function 
insufficiencies doxorubicin should not be used in cats. Oral prednisolone and Chlorambucil is 
the best treatment for low-grade gastrointestinal lymphoma. 
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The mainstay of treatment for lymphoblastic lymphoma is combined chemotherapy (Carolyn 
J. Henry et al., 2010). The combined approach of COP may result in complete remission for 
about 50–70% of treated cats. Doxorubicin as a sole treatment has proven less successful, 
mostly resulting in complete remission rates of less than 50 percent. Still, the most durable 
remissions have been associated with doxorubicin. Thus, the COP Dox protocol is used by 
some clinicians. The most dependable favorable prognostic survival factor, with median 
survival approaching 1 year, appears to be achieving a complete remission. An Australian 
study suggested that 25% of cats achieving complete remission might never relapse, which 
might reflect geographic differences. When complete remission is not achieved, median 
survival drops to a few months.  
Multi-agent chemotherapy is the therapy of choice for high-grade feline gastrointestinal 
lymphoma patients. For feline patients with small-cell or low-grade lymphoma, a treatment 
combination of chlorambucil and orally administrated prednisolone offers good treatment 
modality (Argyle et al., 2008).  
Cats have been administered Lomustine as a primary or rescue agent at a 45.5 - 60 mg/m2 
dosage (Carolyn J. Henry et al., 2010). The dosage appears to be well tolerated. Renal 
lymphoma cats run the risk of CNS metastasis, which can be reduced by adding cytosine-
arabinoside to a COP therapy protocol called: COAP. Radiation therapy has been used to treat 
localized lymphoma, which has proven to be effective particularly for nasal lymphoma. 
Adjunct systemic chemotherapy is typically used to delay or prevent systemic spread of the 
tumor. Cats treated with radiation therapy for nasal lymphoma often have a survival rate 
exceeding 12 months. Alimentary lymphoma cats with complete remission with 
chemotherapy can have a survival time that exceeds 11 months.  Lymphoblastic forms of 
alimentary lymphoma ought to be treated with combination chemotherapy. In a study, 69 
percent of cats with alimentary lymphocytic lymphoma and treated with chlorambucil and 
prednisone reached complete remission, indicating that chlorambucil and prednisone 
combinations are appropriate in the case of indolent lymphomas. 
Monitoring Therapy 
For patients undergoing lymphoma treatment it is necessary to perform serial assessments 
(Argyle et al., 2008). These assessments will differ depending on the extent of the lymphoma, 
the original site, clinical status of the patient, and the therapy protocol. Timely re-evaluations 
should focus on documenting treatment response and make sure the patient is safely 
administered a scheduled treatment 7–10 days after chemotherapy. Physical examination 
should take place 7-10 days after the chemotherapy to ensure remission. Vital signs are 
valuable indicators such as: temperature, heart-rate, respiration-rate, and CBC (complete 
blood count).  If the temperature exceeds 39,4 ºC and PMN <2000 admit to hospital for 
intravenous antibiotics and fluids. If temperature is less than 39,4 ºC and PMN <2000 
prescribe antibiotics. While at home, the owner should monitor the temperature twice a day 
and returns if T >39,4 ºC.  
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Response should be measured on resolution of physical examination and abnormalities, 
biochemical values, resolving clinical signs, and improved hematology (Argyle et al., 2008). 
Measuring response to therapy is essential and it is a poor prognostic indicator in cats, if the 
lymphoma fails to respond to the chemotherapy.  In most cases, cats with lymphoma should 
respond after 3–6 weeks of therapy. If no or poor response is evident within 3-6 weeks, rescue 
therapy or euthanasia should be considered. Not remaining within remission is also a poor 
prognostic factor defined as progressive lymphoma after remission has been achieved with 
proper therapy. Advance of the lymphoma after initial remission as well as failure to respond 
to adequate therapy may be due to chemo-resistance. 
Inflammatory Bowel Disease (IBD) 
IBD is a common malady among domestic cats (August, 2006). In some veterinary hospitals 
and specialty clinics, IBD is the most prevailing gastrointestinal feline malady.  
Three feline bowel problems characterized by random vomiting, chronic diarrhea, and mal-
absorption are classified as inflammatory bowel disease (IBD) (Eldredge et al., 2008).  In 
prolonged cases IBD can lead to weight loss, anemia, and malnutrition. Cats may show 
recurring clinical signs, while others have constant clinical signs. IBD is immune-mediated 
reactions from the gastrointestinal tract to bacteria, parasites, and food.  These reactions get 
over dimensioned, with inflammatory type of cells conjugating in the gastrointestinal tract 
interfering with absorption and digestion. These syndromes are seldom cured but can be 
managed. Over the long run might lead to cancer or ulcers, such as lymphoma. 
The World Small Animal Veterinary Association (WSAVA) Gastrointestinal Standardization 
Group uses the following definition: gastrointestinal clinical signs for duration of more than 3 
weeks, histologic lesions of mucosal inflammation of taken biopsy, inadequate response to 
anthelmintics therapy and dietary modulation, and evidence of clinical response to immune-
modulating treatment.  
IBD Diagnostics 
An IBD diagnosis is an exclusion diagnosis that entails careful elimination of differential 
diagnosis of IBD (Jergens, 2012). After excluding intestinal structural abnormalities, parasitic 
agents, infectious agents, non-gastrointestinal disorders, exocrine pancreatic insufficiency, the 
most prevailing intestinal maladies related to chronic small bowel diarrhea include food-
associated enteropathy, alimentary lymphoma, and idiopathic FIBD. A strict exclusive diet for 
a minimum of seven days effectually eliminates adverse food reactions that can cause diarrhea 
and vomiting in feline patients. The ability to tell the difference between well-differentiated 
lymphoma and severe feline IBD may be particularly tough in cats. Diagnostic methods 
including mucosal biopsies, immunohistochemistry for B-cells and T-cells markers, and PCR 
might help to distinguish alimentary lymphoma from IBD.  
An IBD diagnosis is one of exclusions. It entails the elimination of several other diagnoses 
causing intestinal inflammation (August, 2006). Main differential diagnoses of feline IBD 
include alimentary lymphosarcoma, dietary sensitivity, systemic diseases, infectious diseases, 
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and chronic parasitism. A study showed that up to 30 % of cats with idiopathic 
gastrointestinal signs might be suffering from food sensitivities. Thus, proper diagnostic 
testing should be used to eliminate other causes of chronic intermittent mucosal inflammation, 
and histological evidence and clinical signs should be correlated. Hypoallergenic or 
anthelmintic diets may be appropriate when the patients are suffering from dietary sensitivity 
or parasites. 
IBD Therapy 
The realistic goal of feline IBD is control rather than cure (Eldredge et al., 2008).  In many 
cases, therapy tends to extend for the remainder of the cat’s life. Despite the fact that the 
medication can differ for all three types of IBD, they all typically respond partially or 
completely to changes in diet. Complementary, immune-modulating drugs such as 
azathioprine and prednisolone, antioxidants, omega-3 fatty acids, and probiotics (e.g. 
acidophilus) can be valuable. In order to reduce bacterial count Metronidazole can reduce 
symptoms. Budesonide, a corticosteroid, is being evaluated in the treatment of IBD. However, 
it is too early to recommend. More research is needed. 
Goals of Treatment are to minimize stimulation of antigenic in the gastrointestinal tract and to 
modulate the immune response (Jergens, 2012). Diet is an important part of treatment in all 
three IBD forms. An elimination diet should be easily assimilated, greatly digestible, and low 
in fat. It should consist of a unique protein source and be corn-, milk-, and wheat-free. 
Commercially, hydrolyzed diets such as Royal Canine Feline Hypoallergenic diet and Hill’s 
z/d Ultra Allergen Free are available. Cats with IBD of the colon may benefit from a highly 
digestible fiber e.g. psyllium (Metamucil) 1.7g - 3.4g PO with food q12 to 24h supplement. 
Of all cats with idiopathic gastrointestinal signs, up to 50 percent respond to elimination diets. 
Lymphocytic/ plasmacytic IBD cats can attain clinical remission with diet.  
Chlorambucil; an alkylating agent effective combined with prednisolone for GI small cell 
lymphoma and in many cats with IBD (2.0 mg per cat q48–72h PO), Cyclosporine; an 
immune-modulating drug inhibiting T-cell function effective in cats with refractory IBD (5 
mg/ kg q12 to 24h PO) (Norsworthy et al., 2011).. In case of severe IBD or alimentary 
lymphoma and when biopsy is not an option, it might be necessary with a multimodal 
approach. That is prednisolone, Chlorambucil, hydrolyzed diet, and antibiotics might be 
appropriate. 
IBD Prognosis 
Lymphocytic/plasmacytic colitis can often be managed with an appropriate diet alone 
(Norsworthy et al., 2011). Lymphocytic/plasmacytic IBD is often controllable with proper 
pharmaceutical therapy and diet. Pancreatic or hepatic involvement typically indicates less 
promising prognosis. Less common forms of IBD such as eosinophilic IBD are tougher to 
foretell. 
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Inflammatory Bowel Diseases (IBD) versus High Grade Lymphoma 
IBD is a diagnosis of exclusion that entails elimination of other diseases that may cause 
intestinal inflammation (Hall et al., 2005). Infectious and systemic diseases, dietary allergy 
and intolerance, intestinal parasites, and alimentary lymphoma are the major differential 
diagnoses of IBD. Clinical symptoms must be related to histological gastroenteritis signs, and 
other chronic mucosal inflammation causes should be eliminated by proper diagnostic 
methods. Therapeutic treatments using anthelmintics or hypoallergenic diets may be 
appropriate in cases of parasitic or dietary causes of enterocolitis. Studies indicate that up to 
30% of cats with idiopathic gastrointestinal diseases might suffer from food sensitivities. 
Immunohistochemistry applications may also aid in the diagnosis of alimentary neoplasia 
(Hall et al., 2005). Immunohistochemistry methods are typically used to distinguish between 
an early-stage alimentary lymphoma and lymphocytic FIBD, as it is particularly challenging 
at the histopathological level to distinguish between the two. In the case of lymphoma, the 
infiltrate is clonal, why almost all of the lymphocytes will be of one phenotype. In other 
words, B-lymphocytes or T-lymphocytes will be expected. In the case of an inflammatory 
process a mix of the phenotypes may be found. 
Many gastrointestinal diseases are clinically similar to FIBD, as the gastrointestinal mucosa 
answers to many insults with an inflammation (Norsworthy et al., 2011). Thus, histological 
indication of inflammatory infiltrate alone does not constitute an IBD diagnosis. Differential 
diagnoses to contemplate are allergies, intolerance, parasites, bacterial and other infectious 
agents, i.e. Giardia, nematodes, heartworms, Tritrichomonas, Cryptosporidium, Helicobacter, 
diabetes mellitus, hyperthyroidism, feline immunodeficiency virus, feline leukemia virus, 
salmonellosis, campylobacteriosis, feline infectious peritonitis, adenocarcinoma, alimentary 
lymphoma, chronic renal failure, chronic pancreatitis, exocrine pancreatic insufficiency or 
hepatic disease. Thus, a systematic diagnostic procedure along with a thorough anamnesis is 
critical in order to diagnose IBD with confidence. 
 
MATERIAL OCH METHODS 
Thymidine kinase assay 
TK1 activity was assessed by radiochemical assay using DE-81 filter paper. The following 
was added to the mixture: 20 mM Tris–HCl pH 7.6, 2 mM dithiothreitol (DTT), 5 mM 
MgCl2, 5 mM ATP, 50 µM  [
3
H]-dThd  and 10 µL of serum making the volume 40 µL per 
sample (Sharif  & von Euler et al., 2012).  
20 µL of the reaction mixer was pored in 1,5 mTubes. 10 µL of centrifuged serum and 10 µL 
destilled water was added to each sample.  
The cocktail mixture was incubated for 60 minutes at 37˚C, cooled on ice, spun and 10 µL 
applied on the marked DE-81 filter papers to dry. The filter papers were washed with 1 mM 
ammonium-formate for 5 min twice. Then the filter papers were put in tubes and eluted for 45 
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min in 0.1 M HCl and 0.2 M KCl. Scintillation liquid was added and the samples were 
incubated for 10 minutes. The radioactivity was measured by liquid scintillation counting and 
the activity was expressed as pmol/min/mL. The average per sample was based on 2-3 
thymidine kinase assay results depending on the sample.  
TK REA and assessing TK1 activity 
TK activity in serum was determined using the ProlifigenTK-REA (radio-enzyme assay). This 
assay is based on a radioenzymatic technique in which the substrate analogue 
125I
-
iododeoxyuridine is converted to 
125I
-iododeoxyuridine monophosphate by TK (Von Euler et 
al., 2004). The phosphorylated reaction product is absorbed to a separator tablet (aluminum 
hydroxide). The radioactivity then is measured after several washings. TK activity is reported 
as units per liter (U/L). The TK REA assay was conducted at The Swedish University of 
Agricultural Sciences Laboratories, Uppsala. 
 
RESULTS 
Hypothesis 
The hypothesis was that TK1 activity in serum has the potential to become a valuable 
biomarker in feline clinical practice. Feline TK1 activity in serum from cats with known 
diagnosis was measured with the [3H]-dThd phosphorylation assay. The results were then 
compared with the proven and commercially available TK-REA assay. Several parameters in 
the [3H]-dThd phosphorylation assay were altered in order to optimize, if possible, the assay. 
A possible optimization of the assay allows for improved possibilities of using TK1 as a 
valuable biomarker in feline clinical practice.  
Clinical cases 
Clinical cases were identified at SLU Small Animal Hospital in Uppsala and at The Animal 
Hospital in Jönköping following a search of clinical records for cats with the following 
diagnoses: lymphoma, cystitis, cutaneous lymphosarcoma and leukemia. Cases that were 
subject to TK-REA analysis were included in the study.  
The samples consisted of 12 TK-REA serum samples from 8 cats with an average age of 8,7 
years. The group included 1 intact male, 4 neutered males, and 3 spayed females. Four 
samples from four healthy non-pedigree cats were also included in the study, but not analyzed 
by TK-REA. Results for the healthy cats were 0,05, 0,16, (-0,17), and 0,19 pmol/min/mL.   
Cases of lymphoma were included in the study. Those were diagnosed with lymphoma after 
histopathological or cytological examination of samples. Below table describes how the 
diagnoses by the clinicians were confirmed.   
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Table 1. Diagnosis and assessment method for the samples used 
Samples Diagnosis Assessment method 
5399 Cutaneous lympoma Biopsy 
4739 Leukemia Fine Needle Aspiration 
4471 Leukemia Fine Needle Aspiration 
6318 Malignant lymphoma  Biopsy 
4773 Malignant lymphoma  Biopsy 
4907 Probably malign lymphoma  Fine Needle Aspiration 
6095 Malignant lymphoma  Biopsy 
5206 Acute cystitis Uricult + CLED 
5841 Leukemia Fine Needle Aspiration 
8477 Cutaneous Lymphosarcoma Biopsy 
 
Some of the samples are from the same patient before, during and after therapy indicated in 
the table. Feline leukemia virus (FeLV) status was recorded in each case where available. The 
correlation between average activity using the thymidine kinase assay and the TK-REA test 
used by SLU Laboratory when running both test for eleven samples were 0.97 based on 
Microsoft Excel 2010 “KORREL” function.  The [3H]-dThd phosphorylation assay activity 
had an average of 2.04 with a standard deviation of 2.07 as can be found in the table below. 
All of the samples were from sick cats with various diagnoses. The patient with the highest 
activity level in both tests were a Cornish Rex, four years of age, with the diagnosis leukemia, 
measuring 19.3 in the TK-REA test and 6.02 in the thymidine kinase assay test. The second 
highest level of activity was from a six year old forest cat with cutaneous lymphosarcoma, 
followed by three malignant lymphoma cats, another cat with cutaneous lymphosarcoma, and 
an acute cystitis. The cat with acute cystitis indicates that TK1 serum activity can be 
significantly elevated in not only malignancies but also non-malignancy diseases such as 
cystitis.  
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Table 2. Mean values from the two Serum TK1 assays of samples from 8 cats with date of birth, 
gender, breed and diagnosis as indicated. Samples 4739, 4471 and 5841 are from the same Forest 
Cat, and samples 6318 and 6095 are from the same non-pedigree cat. The cats 6318 and 6095 were 
both tested FeLV negative 
 
 
 
Graph 1. Mean TK1 activity values determined  with the two assays in the samples described in table 
2. 
 
 
 
 
 
TK-REA
Samples Activity Std.dev. Activity Breed DoB Gender Diagnosis
5399 3.75 1.11 5.60 Forest Cat 21-5-2005 spayed Cutaneous lympoma
4739 2.92 1.55 8.50 Cornish rex 22-11-2008 spayed Leukemia
4471 7.44 3.20 19.30 Cornish rex 22-11-2008 spayed Leukemia
6318 0.85 1.17 2.00 Non-Pedigree 15-04-2001 neutered Malign lymfoma
4773 1.15 0.29 1.70 Non-Pedigree 15-09-1999 neutered Malignt lymfoma
4907 1.22 0.41 2.00 Non-Pedigree 01-07-2007 spayed Probably malign lymfoma
6095 0.83 1.10 2.20 Non-Pedigree 15-04-2001 neutered Malignt lymfoma
5206 1.23 1.14 1.60 Non-Pedigree 16-5-1998 neutered Acute cystitis
5841 1.25 0.84 1.00 Cornish rex 22-11-2008 spayed Leukemia
8477 0.84 0.49 2.00 Non-Pedigree 01-06-2010 male Cutaneous lymfosarcoma
TK1 Activity Assay
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Graph 2.  Graph of the linear regression analysis of the test results in table 2, using Microsoft Excel 
2010 and the “KORREL” function . The correlation between the two sets of activity values was 0.97.  
 
Optimizing the 3H phosphorylation assay 
The parameters pH, reaction time, and temperature where altered in order to find out if the 
assay could be optimized. The activities presented are given as pmol/min/mL. 
-pH 
The highest activity measured using the thymidine kinase assay was from the Cornish Rex 
lymphoma cat at pH 6.5. The activity of the sample decreased as the pH decreased or 
increased from pH 7.3, suggesting an optimal pH of 6.5 for maximum enzyme activity.  
However, when measuring the activity from a healthy cat and from a cat with lymphoma, the 
maximum levels of activity were not identical.  The assay does not seem to be sensible to pH 
variations between pH 6.5 - 8.1.  
-Reaction Time   
Sample (4471) from cat with the diagnosis leukemia was tested, using the thymidine kinase 
assay for different time periods; 40, 60, 80, and 100 minutes. The results show that the 
reaction continues in a linear fashion throughout this timespan, suggesting that 60 – 100 
minutes are optimal reaction times for this assay (Graph 3). 
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Graph 3. The graph shows enzyme activity over time in a sample from a cat with leukemia (sample 
4471). Activity is measured in pmol/min/mL. 
-Temperature 
Different temperatures, i.e. 34, 36, 38, 40, 42, and 44 degrees Celsius were used with a 
sample with the diagnosis leukemia (4471). Below the activities are shown, indicating that the 
feline TK1 enzyme activity increased to 38° C (Graph 4). Thus, an optimal temperature is 
most likely around 38° C.  
Temp Activity 
34 3,04 
36 4,33 
38 5,49 
40 2,21 
42 2,85 
44 5,49 
 
Graph 4. Enzyme activity measured at different temperatures in serum from a cat with leukemia. 
Below are the results from the same test but using samples from a healthy cat. The enzyme 
activity in samples from a healthy individual are shown in graph 5, and they appeared to be 
more constant between 36° C and 40° C compared to the cat with leukemia. However, these 
enzymes levels are low, i.e. below the detection limit and are included here mainly to show 
the variation of the background activities. They cannot be used to draw any conclusions 
regarding the stability of serum TK1. 
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Graph 5. Enzyme activity measured in serum from a healthy cat. 
The parameters used in the assay were optimized for canine TK1. The alteration of parameters 
indicates that the temperature may be raised from 37° C to 38° C for optimal feline TK1 
activity. Besides the temperature, it seem like the optimal parameters for canine TK1 are 
similar to those of feline TK1.   
 
DISCUSSION  
The aim of the pilot study was to provide a starting point for future feline TK research. The 
results demonstrate a correlation between the thymidine kinase assay and TK-REA. Both 
assays show a significant increase in TK activity in cats with lymphoma, leukemia and 
cystitis versus clinically healthy cats with a significant correlation, indicating that TK may 
serve as a diagnostic tool in clinical practice. However, the discrepancy in activity level 
between a cat with lymphoma and a healthy cat is not as clear cut as the difference in activity 
level between a dog with lymphoma and a healthy dog. 
TK1 is used as a biomarker in clinical oncology to assist with early diagnosis of malignancy, 
prognosis of tumors, response to therapy evaluation and relapse detection (Von Euler & 
Eriksson, 2011).  
Previous results revealed that the dThd phosphorylation assay is suitable for measurement of 
TK1 in hematologic malignancy (lymphoma and leukemia) in dogs and provided valuable 
information regarding the disease recurrence. Significant correlations were observed between 
the [
3
H]-dThd assay and the two commercial TK1 activity assays (Sharif & von Euler et al, 
2012).  
Even though this study showed that samples from a leukemia-patient and a cystitis-patient 
had distinguishable activity levels, Pelle (8477) a cat with cutaneous lymphosarcoma, had an 
activity level, which was difficult to distinguish from a healthy cat. 
Taylor’s study shows there is a considerably higher serum TK activity in cats with lymphoma 
than in, cats with inflammatory diseases, or cats with non-hematopoietic neoplasia, or healthy 
cats (Taylor et al., 2012). These findings suggest that serum TK activity is a biomarker for 
feline lymphoma. However, the ROC analysis in Taylor’s study showed a relatively low 
sensitivity for the Prolifigen TK-REA; DiaSorin technique, i.e. with several lymphoma cases 
Temp Activity 
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having values within the reference interval. However, a high TK serum activity level was 
greatly indicative of a lymphoma diagnosis, while there is a very low predictability for cats 
with low TK serum activity level.  
The preliminary study presented here show similar results. Thus, further research is needed in 
order to use feline TK1 activity measurements in serum as a reliable clinical biomarker. 
Furthermore, TK1 protein concentrations in serum should be analyzed in order to better 
understand the role of feline TK1 as a diagnostic biomarker. In many disorders the amount of 
protein can be more indicative than the protein activity. An ELISA based essay using 
antibodies measuring protein concentration versus the activity would most likely be 
beneficial. 
Serum TK1 is most likely present in the blood of healthy cats. However, in the healthy cats 
the TK1 serum activity could not be quantified using the [
3
H]-dThd phosphorylation assay. 
As samples were scarce, a larger study with more samples should be done and will be more 
conclusive.  
The complexity of the TK1 protein in serum is most likely a major contributing factor for the 
difficulty in developing effective determination methods (Sharif & Kiran et al., 2012). Sharif 
et al found that serum TK1 exists in a mixture of different molecular sizes, and that only a 
fraction of the TK1 protein in serum is associated with TK1 activity. Reducing agents had a 
negative effects on serum TK1 activity but may be important in order to determine the TK1 
protein levels with immunochemical methods. 
This study shows that TK1 as a biomarker can be used to distinguish a cat with leukemia or a 
cat with cystitis from a healthy cat. 
Feline inflammatory bowel diseases, allergies and intestinal lymphoma are commonly 
encountered maladies in clinical practice and difficult to tell apart. TK1 determinations in 
serum may serve as a biomarker provided and adequately sensitive TK1 assays may be able to 
aid with the differential diagnosis.  
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